Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ALB | P02768 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24478476 | 0.83 | CYP3A4 (0.43) | RECQLALDH1A1KDM4ESMN1; SMN2MEN1 | |
| SCHEMBL22714758 | 0.78 | ALDH1A1 (0.59) | ALDH1A1KDM4ENPSR1PKMSMN1; SMN2 | |
| SCHEMBL31494280 | 0.78 | ALOX5AP (0.41) | ALDH1A1KDM4ENPSR1MEN1KMT2A | |
| SCHEMBL24478422 | 0.78 | ALOX5AP (0.41) | ALDH1A1KDM4ENPSR1MEN1KMT2A | |
| SCHEMBL4739150 | 0.73 | GSTO1 (0.50) | ALDH1A1KDM4ENPSR1PKMSMN1; SMN2 | |
| SCHEMBL4760475 | 0.72 | LMNA (0.74) | ALDH1A1SMN1; SMN2MEN1KMT2ALMNA | |
| SCHEMBL1990490 | 0.72 | ALDH1A1 (0.61) | ALDH1A1KDM4ENPSR1PKMSMN1; SMN2 | |
| SCHEMBL11177460 | 0.71 | PKM (0.58) | ALDH1A1KDM4ENPSR1PKMSMN1; SMN2 | |
| SCHEMBL11181821 | 0.71 | PKM (0.54) | RECQLPKMSMN1; SMN2MEN1KMT2A | |
| SCHEMBL730137 | 0.71 | KDM4E (0.58) | RECQLKDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12466820-B2 | Amino quinazoline derivatives as P2X3 inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-11-11 | — | — | US | disclosed |
| EP-4251620-B1 | AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS | CHIESI FARM SPA (IT) | 2025-04-16 | — | — | EP | disclosed |
| CN-113891745-B | As P2X3Aminoquinazoline derivatives of inhibitors | 奇斯药制品公司 | 2024-05-07 | — | — | CN | disclosed |
| US-20240025880-A1 | AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-01-25 | — | — | US | disclosed |
| US-20240025880-A1 | AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-01-25 | — | — | US | disclosed |
| US-20240025880-A1 | AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-01-25 | — | — | US | disclosed |
| EP-4251620-A1 | AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2023-10-04 | — | — | EP | disclosed |
| CN-116601149-A | Aminoquinazoline derivatives as P2X3 inhibitors | 奇斯药制品公司 | 2023-08-15 | — | — | CN | disclosed |
| US-20220227749-A1 | AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS | CHARLES RIVER LABORATORIES, INC. | 2022-07-21 | — | — | US | disclosed |
| WO-2022112490-A1 | AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2022-06-02 | — | — | WO | disclosed |
| WO-2022112490-A1 | AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2022-06-02 | — | — | WO | disclosed |
| EP-3976180-A1 | AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2022-04-06 | — | — | EP | disclosed |
| CN-113891745-A | As P2X3Aminoquinazoline derivatives as inhibitors | 奇斯药制品公司 | 2022-01-04 | — | — | CN | disclosed |
| WO-2020239952-A1 | AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2020-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220227749-A1 | AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS | P2RX3, P2RX5, P2RX1 | RECQL 535/4885ALDH1A1 1918/4885KDM4E 3667/4885 |
| US-12466820-B2 | Amino quinazoline derivatives as P2X3 inhibitors | P2RX3, P2RX5, P2RX1 | RECQL 535/4885ALDH1A1 1918/4885KDM4E 3667/4885 |
| US-20240025880-A1 | AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS | P2RX3, P2RX5, P2RX1 | RECQL 535/4885ALDH1A1 1918/4885KDM4E 3667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.